Press release: sanofi and regeneron's dupixent to treat chronic spontaneous urticaria advances in eu with positive chmp opinion

Sanofi and regeneron's dupixent to treat chronic spontaneous urticaria advances in eu with positive chmp opinion recommendation for adults and adolescents based on phase 3 studies showing dupixent significantly reduced itch and hives at 24 weeks compared to placebo if approved, dupixent would be the first targeted medicine in over a decade indicated for csu in the eu paris and tarrytown, september 22, 2025. the european medicines agency's committee for medicinal products for human use (chmp) has adopted a positive opinion recommending the approval of dupixent (dupilumab) in the eu for the treatment of chronic spontaneous urticaria (csu) in adults and adolescents.
REGN Ratings Summary
REGN Quant Ranking